Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.

8078^ Background: Prior results from the first-in-human phase I study (ASCEND-1) of the novel ALK inhibitor (ALKi) ceritinib (LDK378), demonstrated high response rates in crizotinib (CRZ)-naive and...